European Journal of Medicinal Chemistry p. 10 - 21 (2013)
Update date:2022-08-15
Topics:
Hernández-Vázquez, Eduardo
Aguayo-Ortiz, Rodrigo
Ramírez-Espinosa, Juan José
Estrada-Soto, Samuel
Hernández-Luis, Francisco
Diabetes and obesity are two universal health problems that constitute a research objective of several groups due to the lack of efficient and safe drug treatment. In this sense, cannabinoid receptor 1 (CB1) has attracted interest because of its role in food intake and metabolic balance, two targets in the control of metabolic syndrome. In this work, novel 1,5-diaryl pyrazole derivatives were synthesized in accordance with the pKi prediction of a previously reported CoMFA model by our group. To further investigate the biological activity of these compounds in metabolic disorders, their hypoglycemic activity in an in vivo model was tested. Interestingly, a high degree of correlation was observed between the predicted pKi and hypoglycemic effect 7 h after administration. Compounds 4, 9 and 13 showed the most significant plasma glucose reduction with decreases of 60%, 64% and 60% respectively. This result not only surpasses the activity of the lead rimonabant, but also that of the reference drug glibenclamide. Moreover, PASS prediction and molecular docking in an excellent validated homology model of CB1 suggest that these compounds would probably act as CB1 antagonists/inverse agonists and therefore, anti-obesity agents. The ligand-receptor complexes demonstrate that 1,5-diaryl pyrazole derivatives bind to the proposed binding site where a hydrophobic moiety interacts with the phenyl rings in the pyrazole nucleus and Lys192 forms a hydrogen bond with the oxygen of the carbonyl group. Dynamics simulations were also carried out to study the stability of the ligand-receptor complexes where the most active compounds showed smaller ΔG values and more hydrogen bonds throughout the simulation. These compounds are considered useful leads for further optimization in the treatment of such metabolic illnesses.
View MoreChengdu ZY Biochemical Technology Co., LTD
Contact:0086-28-88680086
Address:170 Qingpu Road, Shouan Town, Pujiang County
Engineering Research Center of Pesticide, Heilongjiang Province
Contact:+86-451-86609001
Address:No.74 of Xuefu Road, Nangang District,
Yueyang Hudex Pharmaceuticals Ltd.
Contact:0730-8748800
Address:Wujiang Bridge,Yueyang Economy & Technology Development Zone
Tianjin Pharmacn Medical Technology Co.,Ltd.
Contact:86-22-60122566ext.866(English),23359620
Address:Green Industrial Base, 6 Haitaifazhan Sixth Rd., Huayuan Industrial Area, Tianjin, 300384, China
Contact:+86-021-6989-5597
Address:No.80 Yichuan Rd., Putuo District,Shanghai,P.R.China
Doi:10.1039/c39930000436
(1993)Doi:10.1021/jo00066a023
(1993)Doi:10.1021/jo00017a021
(1991)Doi:10.1016/j.tetasy.2012.01.005
(2012)Doi:10.1007/BF00770626
(1992)Doi:10.1002/chem.202000517
(2020)